Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 75 versus IOPAMIDOL 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 75 versus IOPAMIDOL 250.
HYPAQUE-M,75% vs IOPAMIDOL-250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast due to high iodine content. It increases the density of vascular structures and tissues, allowing visualization of anatomical structures during imaging procedures.
Iopamidol is a non-ionic, water-soluble, iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing vascular and tissue contrast during imaging procedures. It acts by increasing the radiodensity of blood vessels and organs.
1.2-1.5 mL/kg IV as a single dose for CT enhancement; maximum 150 mL per procedure.
1-2 mL/kg intravenously for contrast imaging, not to exceed 200 mL total; dose and rate vary by procedure and patient weight.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
Terminal half-life 1.5-2 hours in normal renal function; may extend to 5-10 hours in severe renal impairment (CrCl <30 mL/min)
Renal excretion: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Renal: >90% unchanged via glomerular filtration; biliary/fecal: <2%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent